Company Profile

Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company's licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

25/23/25	Apexigen, Inc.(NasdaqCM:APGN) dropped from S&P TMI Index	CI
23/23/23	Pyxis Oncology Completes Acquisition of Apexigen	MT
23/23/23	Apexigen, Inc.(NasdaqCM:APGN) dropped from NASDAQ Composite Index	CI
23/23/23	Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	CI
11/23/11	Apexigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
03/23/03	Apexigen, Inc. Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology 2023 Annual Meeting	CI
24/23/24	Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	MT
24/23/24	Apexigen, Inc., Pyxis Oncology, Inc. - M&A Call
24/23/24	US Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes Release	MT
24/23/24	Top Premarket Gainers	MT
24/23/24	Pyxis Oncology to Acquire Apexigen in $16 Million All-Stock Deal	MT
16/23/16	EF Hutton Adjusts Price Target on Apexigen to $5 From $8, Maintains Buy Rating	MT
16/23/16	Apexigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

16/23/16	EF Hutton Adjusts Price Target on Apexigen to $5 From $8, Maintains Buy Rating	MT
24/23/24	Roth Capital Reinstates Apexigen at Buy Rating With $15 Price Target	MT
05/23/05	EF Hutton Starts Apexigen at Buy With $8 Price Target	MT
17/22/17	Roth Capital Starts Apexigen at Buy with $13 Price Target	MT

11/23/11	APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN	BU
03/23/03	Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting	AQ
31/23/31	APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN	BU
24/23/24	Pyxis Oncology to Acquire Apexigen	AQ
13/23/13	APEXIGEN, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ

Manager	Title	Age	Since
Ronald Levy PRN	Corporate Officer/Principal	-	-
Brian Daniels PRN	Corporate Officer/Principal	67	-
David Ho PRN	Corporate Officer/Principal	73	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/08/23	Scott Smith	Issuer sale	Director	1,34,084	0.5396%
23/08/23	Frank Hsu	Issuer sale	Chief Technology Officer	2,68,226	1.0794%
23/08/23	Meenu Chhabra Karson	Issuer sale	Director	1,00,000	0.4024%

Apexigen, Inc. Share Price

Stocks

APGN

US03759B1026

Biotechnology & Medical Research

Latest news: Apexigen, Inc.

Analysts' recommendations: Apexigen, Inc.

Press Releases: Apexigen, Inc.

Quotes and Performance

Managers and Directors: Apexigen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APEXIGEN, INC.	-6.68%	-10.97%	-	-	95.74L
WUXI APPTEC CO., LTD.	-3.10%	-3.43%	+36.29%	+67.69%	6.53TCr
ARGENX SE	+0.33%	+7.26%	+11.51%	+77.95%	5.46TCr
LONZA GROUP AG	+0.16%	+3.69%	+8.39%	+101.27%	5.36TCr
IQVIA HOLDINGS INC.	-0.75%	+2.13%	+23.14%	+47.25%	4.5TCr
BEONE MEDICINES AG	-1.30%	-1.11%	+17.77%	+120.71%	4.22TCr
REVOLUTION MEDICINES, INC.	+1.26%	+2.23%	+241.81%	+835.31%	3.94TCr
CELLTRION, INC.	-0.74%	-4.84%	+14.53%	+44.45%	3.27TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	-7.34%	+23.17%	+0.36%	2.4TCr
GENMAB A/S	+1.11%	+17.90%	+56.87%	+47.78%	2.65TCr
Average	-1.25%	+1.98%	+48.16%	+149.20%	4.26TCr
Weighted average by Cap.	-0.73%	+1.72%	+45.16%	+148.64%